Market Spotlight: Multiple Sclerosis Forecast
DISEASE OVERVIEW
Multiple sclerosis (MS) is an inflammatory, autoimmune disease characterized by neuronal
demyelination leading to physical and cognitive disability. Although the etiology of MS is
uncertain, it is thought to involve genetic, environmental, and infectious disease
components. Current therapies for MS largely fall into two categories: symptomatic and
disease-modifying, and both are frequently used in combination with one another.
MARKET SNAPSHOT
Ocrevus’s peak sales estimate increases as early data suggest it is competing across a
range of treatment settings.
Despite the approvals of newer, more efficacious therapies, Copaxone and interferon beta
remain key components of treatment practices in MS.
An overall increase in diagnosed prevalent MS cases is expected, despite declines in
markets experiencing negative population growth.
Exciting newcomer Ocrevus is gaining considerable traction in only its first year of
commercial availability.
Celgene must balance ozanimod pricing to maximize MS opportunity while ensuring
reimbursement in secondary indications.
Products targeting progressive disease types will have favorable reimbursement.
Exclusive Sample Report @
https://www.reportsworldwide.com/enquiry?report_id=42618
CONTENTS
FORECAST: MULTIPLE SCLEROSIS (Published on 24 November 2017)
EXECUTIVE SUMMARY
RECENT FORECAST UPDATES
MARKET DYNAMICS
FORECAST AND FUTURE TRENDS
MARKET DEFINITION AND METHODOLOGY
PRIMARY RESEARCH METHODOLOGY
BIBLIOGRAPHY
PRODUCT PROFILE (LATE STAGE): ALKS 8700
PRODUCT PROFILE: AUBAGIO
PRODUCT PROFILE: AVONEX
PRODUCT PROFILE: BETASERON
PRODUCT PROFILE: COPAXONE
PRODUCT PROFILE: GILENYA
PRODUCT PROFILE: LEMTRADA
CONTINUED……………………………
LIST OF FIGURES
Figure 1: Multiple sclerosis – current and future market dynamics analysis
Figure 2: Datamonitor Healthcare’s assessment summary of key marketed and pipeline drugs for
multiple sclerosis
Figure 3: Multiple sclerosis market sales across the US, Japan, and five major EU markets, by country,
2016–25
Figure 4: Growth dynamics of the multiple sclerosis market across the US, Japan, and five major EU
markets, by country, 2016–25